Taisho Pharmaceutical to Launch OTC-switched Zaditen Nasal Solution.Tokyo, Japan, Aug 4, 2005 - (JCNN JCNN Japan Corporate News Network ) - Taisho Pharmaceutical (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4535) announced on August 3 that it has received approval from the Ministry of Health, Labor and Welfare for an OTC-switched version of Zaditen Nasal Solution, an antiallergic an·ti·al·ler·gic adj. Preventing or relieving allergies. antiallergic adjective Countering allergy or an allergic state agent developed by Novartis Pharma. Taisho will distribute OTC-switched Zaditen as its Pabron series through pharmacies across Japan while Novartis Pharma will import it. Containing ketotifen fumarate as a main ingredient, the product helps alleviate nasal allergy symptoms due to pollen and house-dust mites. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion